PAK1-blockers: Potential Therapeutics against COVID-19.


Maruta H, He H




Med Drug Discov. 2020 Apr 19:100039.

Publication Link:

DOI Link:

PAK1 (RAC/CDC42-activated kinase 1) is the major “pathogenic” kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19.

Since Louis Pateur who developed a vaccine against rabies in 1885, in general a series of “specific” vaccines have been used for treatment of viral infection, mainly because antibiotics in general are ineffective for treatment of viral infection. However, it takes 12-18 months till the effective vaccine becomes available. Until then ventilator (O2 supplier) would be the most common tool for saving the life of COVID-19 patients.

Thus, as alternative potentially more direct “broad-spectrum” COVID-19 therapeutics, several natural and synthetic PAK1-blockers such as propolis, melatonin, ciclesonide, hydroxy chloroquine (HQ), ivermection, and ketorolac, which are readily available in the market, are introduced here.

© 2020 Published by Elsevier B.V.

Scroll to Top